well, did your extensive DD find out that the key statistics on yahoo finance are totally wrong. They just raised 21.8 million dollars. Great DD dude!
#$%$ Sorry!! What I meant was FDA denial expected April 2!! Capital raise of 21 million also needs to be returned at 20% interest. Bankruptcy imminent!!
Read the transcript: FDA clearance expected first week in April according to March 16 Conference call
You mean like JAZZ and Teva, some of the biggest biotechs around. JAZZ up from 0.8 to 170 in 5 years???? Nope dont buy an Israeli biotech. HMMM the La Jolla of biotech outside the US.
from skin lesion and perhaps BL1040. This number has been going up every week. I expect positive cash flow by next year and never again needing to sell shares.
Yes. They bought from BLRX - this was a cash raise. Mentioned in the Roth meeting as a capital raise! 100% sure
Cash position is 68.3 million dollars - ROTH presentation. 29.6 cash starting plus 10 million from NVT and 28.6 from secondary.
About 52 million outstanding shares
expected 1040 market 1 billion in the near term. Lets not forget people 1040 is CLOSE to marketing. It is almost ready to go!!
BL1040 could bring in over 250 million short term from milestones NOT COUNTING 10-11% royalties. Considered a potential "BLOCKBUSTER"
blockbuster companies have market caps over 10 billion.
Expected revenue stream from Skin Lesion product and BL1040 cardiac product in 2016.
60 million in Cash,
Bellepheron collaboration and sales,
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Omega Pharma, Genoscience and Panmed.
This company is a multi-billion dollar company in its infancy. What better time to get in?? Especially below the offering to Novartis and secondaries.
Only reason it is going down is daytraders and shorts (who got in simply because of the appreciation of the stock price) who have zero interest or knowledge of the company. Any real long term investor selling now is foolish extremely foolish IMO
There was the same kind of deal. Development of a product jointly. Glaxo bought above market and then the price fell considerably. A month or two later there was news on a drug candidate which sent the stock soaring 200%.
CANF appears to need capital and one strategy is to wait for a secondary but by that time, the shares could be at 12. They may also get a non-dilutive cash infusion or sell shares higher than the market price (this happens quite often - one example is Bristol Meyers buying a huge stake in FPRX at a 30% premium last year). CANF also burns only a couple million a quarter, which is less than BLRX
yes, I know what you are saying. Many biotechs are duds and the majority have just one or two drug candidtates in highly competitive markets. I like BLRX and CANF (and FPRX to some extent) because they have many candidates in a variety of markets and have outstanding Phase I, II III and even later (in the case of 1040) results.
Now, it is hard to wrap ones head around the kind of appreciation possible but with such low market caps, both CANF and BLRX have a possibility of 100x returns. Has this happened? Yes. More than you think. One example - JAZZ in 2009 was 0.60 cents. Now it is 170 or about a 300x gain in 6 years. CELG another. and many more
you have a pipeline that rivals BIIB but priced at 1/1000 of the price of BIIB:
BIIB 100 billion market cap
BLRX and CANF - 120 million
The pipeline between these two companies cannot lose. 4-7 years from now you will turn 10k into at least 2 million. mark this post if yahoo is still around in 6-7 years.